Sotera Health president Rutz sells $2.83m in common stock

Michael P. Rutz, the President of Sterigenics, a subsidiary of Sotera Health Co (NYSE:SHC), sold 150,000 shares of the company's common stock on August 7, 2026. This sale amounted to approximately $2,825,250. The stock was trading near its 52-week high of $19.85, with shares currently priced at $18.89. The company boasts a market capitalization of $5.43 billion and a P/E ratio of 33.34.

The shares were sold at prices ranging from $18.75 to $18.9050 per share, with an average weighted price of $18.835. As a result of this transaction, Rutz retains 334,279 shares of Sotera Health common stock directly. According to InvestingPro analysis, the stock appears to be overvalued compared to its Fair Value. Investors interested in more detailed analysis can access Pro Research Reports for SHC and 1,400+ US equities.

Sotera Health recently reported strong second-quarter earnings, exceeding Wall Street's predictions. The company reported adjusted earnings of $0.26 per share, surpassing the expected $0.24, with revenue of $321.37 million, also surpassing the forecasted $309.64 million. This performance represents a 9.2% increase in revenue year-over-year, accompanied by a 10% increase in adjusted EBITDA and improved margins.

Management has since raised their full-year 2026 revenue, adjusted EBITDA, adjusted EPS, and interest expense outlook. The Sterigenics, Nordion, and Nelson Labs business units all experienced growth, contributing to this positive financial outcome. Furthermore, Sotera Health has reached its long-term leverage target and concluded the quarter with approximately $950 million in liquidity.

Additionally, James C. Neary has resigned from the company's Board of Directors, with Sotera Health stating that Neary's departure was not due to any disagreements about company operations or policies.